News & Promotions

Provide total solutions for Life Science applications together with global partners. We are constantly striving to be more
connected, forward-looking and customer-focused to deliver best results.

News & Promotions

News

[Life Diagnostics] SPARCL™[1] – A Simpler and Faster ELISA Alternative

관리자 2024.06.18 15:28 조회 111 추천 2
banner.jpg




SPARCL™[1] – A Simpler and Faster ELISA Alternative


240618-0-1.jpg



SPARCL™ (Spatial Proximity Analyte Reagent Capture Luminescence) assays use two specific antibodies; one conjugated to HRP, the other to acridan, a chemiluminescent substrate. When HRP and acridan conjugated antibodies bind to their target biomarker they are brought into close proximity. Upon addition of hydrogen peroxide (trigger solution), HRP catalyzes oxidation of proximal acridan molecules causing a flash of chemiluminescence that is proportional to biomarker concentration. Acridan molecules distant from HRP are not oxidized and therefore produce no luminescence. This principle allows development of a range of rapid and sensitive homogeneous immunoassays.


       
그림9.jpg          240618-3.jpg      


A typical SPARCL™ assay requires no wash steps, uses a single incubation, and takes approximately 45 minutes start to finish. This contrasts with ELISA’s that require 1-4 incubations, 1-3 wash steps and take 2-4+ hours. SPARCL™ kits require a luminometer capable of simultaneous injection and measurement. Click here to find out if your luminometer is compatible. Click here for answers to SPARCL FAQs.

Currently available SPARCL™ kits are listed below. Click on the catalog numbers for the kit instructions.

A list of publications that have used our SPARCL™ assays can be found at the bottom of this page.


SPARCL™ Literature References

1.Baka R, et al. Quantitative proteomics of cerebrospinal fluid using tandem mass tags in dogs with recurrent epileptic sezuresJ Proteomics 231:1039777 (2021)
2.Kules J, et al. The plasma proteome and the acute phase protein response in canine pyometra. J Proteomics 223:103817 (2020)
3.Liu M, et al. Cardiovascular-renal axis disorder and the acute-phase proteins in cats with congestive heart failure caused by primary cardiomyopathy. J Vet Intern Med. 34)3):1078-1090 (2020)
4.Dalanezi FM, et al. Concentrations of acute phase proteins in milk from cows with clinical mastitis caused by different pathogens. Pathogens 9(9):706 (2020)
5.Boulay I, et.al. SPARCL™: Use of a novel technology in validation of a Non-human primate and rat cardiac troponin-I assay in serum. CiToxLAB, 2016

6.Boulay I, et.al. SPARCL™: Use of a Novel Technology in Validation of a Non-Human Primate C-Reactive Protein Assay in Serum. CiToxLAB. 2016

SPARCL™ Case Studies – Third party evaluations of SPARCL™ technology
1. 
Johnson and Johnson
2. 
Monsanto
3. 
Lumigen – Human IgG kit (IGG-SP-20)

[1] The SPARCL™ technology was developed by Lumigen Corp.



Products


240618-2.jpg

logo-partner.jpg


하단배너-1200.jpg